Cannabinoid-2 agonists

Patent metadata

Field	Value
Publication number	US-9670216-B2
Application number	US-201514746562-A
Country	US
Kind code	B2
Filing date	Jun 22, 2015
Priority date	Feb 8, 2010
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 agonists.

First claim

We claim:

1. A compound of Formula III or Formula IV or a pharmaceutically acceptable salt thereof:

wherein:
X is N;
R 1 is H;
R 2 is C 1 -C 6 alkyl or C 2 -C 6 alkyl substituted by N(R 4 R 5 ), wherein R 4 and R 5 are C 1 -C 4 alkyl or R 4 and R 5 together form a morpholine ring; and
Q is the ring-structure of Formula II:

2. The compound of claim 1 , wherein the cannabinoid-2 agonist is 1-Propyl-5-(3,3,5,5-tetramethyl cyclohexyl)pyrazolo[3,4-d]pyridazin-4-one, 2-Propyl-5-(3,3,5,5-tetramethylcyclohexyl)pyrazolo[3,4-d]pyridazin-4-one, 1-(2-Morpholin-4-ylethyl)-5-(3,3,5,5-tetramethylcyclohexyl)pyrazolo[3,4-d]pyridazin-4-one, 2-(2-Morpholin-4-ylethyl)-5-(3,3,5,5-tetramethylcyclohexyl)pyrazolo[3,4-d]pyridazin-4-one, 1-(2-Dimethylaminoethyl)-5-(3,3,5,5-tetramethylcyclohexyl)pyrazolo[3,4-d]pyridazin-4-one, or 2-(2-Dimethylaminoethyl)-5-(3,3,5,5-tetramethylcyclohexyl)pyrazolo[3,4-d]pyridazin-4-one.

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

5. A method of treating an eye related syndrome, disorder or disease selected from the group consisting of abnormal intraocular pressure, allergic keratitis, uveitis, or iritis, conjunctivitis, blepharitis, neuritis nervi optici, choroiditis, glaucoma and sympathetic ophthalmia in a subject suffering from said syndrome, disorder of disease, comprising administering to said subject a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof.

6. A method of treating an eye related syndrome, disorder or disease selected from the group consisting of abnormal intraocular pressure, allergic keratitis, uveitis, or iritis, conjunctivitis, blepharitis, neuritis nervi optici, choroiditis, glaucoma and sympathetic ophthalmia in a subject suffering from said syndrome, disorder of disease, comprising administering to said subject a therapeutically effective amount of at least one compound of claim 5 or a pharmaceutically acceptable salt thereof.

Assignees

• Allergan Inc

Inventors

• Chen June
• Pettit Simon
• Fliri Hans

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/12

  Antihypertensives · CPC title